32,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
In Alzheimer's disease, the spread of aberrantly phosphorylated tau is an important criterion in the Braak staging of disease severity and correlates with disease symptomatology. 4 key findings →
Participants: 654 Evidence: high
Full summary, score breakdown and related studies → Original source
The pooled evidence did not confirm a statistically significant reduction in VaD risk with GLP-1 RA therapy. 5 key findings →
Design: systematic review Participants: 61,610 Evidence: high
Full summary, score breakdown and related studies → Original source
Tau protein aggregation, a key pathological feature of AD, is closely associated with neurodegeneration and cognitive decline. 5 key findings →
Design: systematic review Participants: 2,193 Evidence: high
Full summary, score breakdown and related studies → Original source
Targeting of tau pathology has long been proposed as a potential therapeutic strategy for Alzheimer's disease (AD). 5 key findings →
Design: clinical trial Evidence: high
Full summary, score breakdown and related studies → Original source
In a large international cardiovascular outcome trial in people with type 2 diabetes and cardiorenal disease, linagliptin did not modulate cognitive decline over 2.5 years. 2 key findings →
Participants: 1,545 Evidence: high
Full summary, score breakdown and related studies → Original source
Four RCTs comprising 112 patients (61 placebo, 51 treatment) were included. 5 key findings →
Design: meta-analysis Participants: 112 Evidence: high
Full summary, score breakdown and related studies → Original source
Emerging evidence suggests that antidiabetic agents may offer neuroprotective effects by targeting shared pathophysiological mechanisms such as insulin resistance and neuroinflammation. 5 key findings →
Design: meta-analysis Participants: 7,361 Evidence: high
Full summary, score breakdown and related studies → Original source
In adults ≥65 years of age, statin therapy was not associated with incident dementia, MCI, or declines in individual cognition domains. 4 key findings →
Design: randomized controlled trial Participants: 18,846 Evidence: high
Full summary, score breakdown and related studies → Original source
There was no change in the primary outcome. 5 key findings →
Participants: 32 Evidence: high
Full summary, score breakdown and related studies → Original source
Fifty-eight of 77 patients (75.3%) completed the trial. 5 key findings →
Participants: 77 Evidence: high
Full summary, score breakdown and related studies → Original source
In participants with long-standing T2DM and at high risk for cardiovascular events, intensive BP control and fibrate therapy in the presence of controlled low-density lipoprotein cholesterol levels did not produce a measurable effect on cognitive decline at 40 months of follow-up. 4 key findings →
Participants: 1,439 Evidence: high
Full summary, score breakdown and related studies → Original source
The prespecified primary analyses did not show any treatment benefit at either of the doses tested for the coprimary outcomes (change in ADAS-Cog score compared with control [n=354, 6·32, 95% CI 5·31-7·34]: 75 mg LMTM twice a day [n=257] -0·02, -1·60 to 1·56, p=0·9834, 125 mg LMTM twice a day [n=250] -0·43, -2·06 to 1·20, p=0·9323; change in ADCS-ADL score compared with control [-8·22, 95% CI -9·63 to -6·82]: 75 mg LMTM twice a day -0·93, -3·12 to 1·26, p=0·8659; 125 mg LMTM twice a day -0·34, -2·61 to 1·93, p=0·9479). 3 key findings →
Participants: 354 Evidence: high
Full summary, score breakdown and related studies → Original source
We developed an endophenotype disease module-based methodology for Alzheimer's disease (AD) drug repurposing and identified sildenafil as a potential disease risk modifier. 2 key findings →
Design: case-control study Evidence: high
Full summary, score breakdown and related studies → Original source
No significant between-group effects of exenatide on ADAS-Cog11 score (p = 0.17) were detected. 5 key findings →
Participants: 17 Evidence: high
Full summary, score breakdown and related studies → Original source
EQW affected FCN2 (Cohen's d -0.019), PAI-1 (Cohen's d -0.033), sVCAM-1 (Cohen's d 0.035) and a cytokine-cytokine cluster (Cohen's d 0.037) significantly compared with placebo. 4 key findings →
Participants: 13,752 Evidence: low
Full summary, score breakdown and related studies → Original source
The parent molecule, PT3, was raised against Alzheimer's disease brain purified paired helical filament, and preclinical studies with the humanized version, JNJ-63733657, have demonstrated reductions in tau seeding. 5 key findings →
Design: clinical trial Participants: 13 Evidence: high
Full summary, score breakdown and related studies → Original source
Intensive treatment to lower systolic blood pressure did not result in a clinically relevant difference compared with standard treatment in memory or processing speed in a subgroup of participants from SPRINT. 3 key findings →
Design: randomized controlled trial Participants: 2,800 Evidence: high
Full summary, score breakdown and related studies → Original source
In this large real-world cohort, GLP-1 RAs were associated with lower dementia risk than DPP4is but higher risk than SGLT2is. 5 key findings →
Design: cohort study Participants: 6,677 Evidence: moderate
Full summary, score breakdown and related studies → Original source
In this study, suvorexant acutely decreased tau phosphorylation and amyloid-β concentrations in the central nervous system. 3 key findings →
Design: randomized controlled trial Participants: 13 Evidence: high
Full summary, score breakdown and related studies → Original source
In a randomized, placebo-controlled, double-blind study, we investigated whether statins alter cholesterol metabolites and reduce Abeta levels in the cerebrospinal fluid of 44 patients with Alzheimer's disease. 2 key findings →
Participants: 44 Evidence: high
Full summary, score breakdown and related studies → Original source
Statin therapy was not associated with cognitive impairment in RCTs. 5 key findings →
Design: meta-analysis Participants: 46,836 Evidence: high
Full summary, score breakdown and related studies → Original source
Participants in the placebo group displayed cognitive and functional decline, whereas lithium-treated patients remained stable over 2 years. 4 key findings →
Participants: 61 Evidence: high
Full summary, score breakdown and related studies → Original source
Treatment with GLP-1 RAs may provide a new opportunity to reduce the incidence of dementia in patients with type 2 diabetes. 2 key findings →
Participants: 15,820 Evidence: high
Full summary, score breakdown and related studies → Original source
Diabetes and hyperinsulinemia may be risk factors for Alzheimer's disease (AD). 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
If the primary end points are met, the data will provide confirmatory evidence of the clinical and biomarker benefits of hydromethylthionine mesylate in minimal to moderate AD. 1 key finding →
Design: clinical trial Participants: 545 Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 32,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 32,180 records, built mostly from automated pulls of Europe PMC (66.5% of the library) and OpenAlex (15.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,045 records (3.2% of the library) are not peer-reviewed — 966 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events
Last updated